Contributor: Hanxi Zhang,Jamie C Barner,Leticia R Moczygemba,Karen L Rascati,Chanhyun Park,Dhatri Kodali From: physiciansweekly.com This study aimed to compare survival outcomes of neoadjuvant (NAC) and adjuvant chemotherapy (AdC) within each breast cancer subtype and stage among older women. Older (≥ 66 years) women newly diagnosed with stage I-III invasive ductal breast cancer during 2010-2017 and treated with both chemotherapy and surgery within …
KEYNOTE-522: Neoadjuvant and Adjuvant Pembrolizumab in TNBC
By: Joyce A. O’Shaughnessy, MD, Sara A. Hurvitz, MD From: onclive.com Expert perspectives on adjuvant and neoadjuvant use of pembrolizumab in the KEYNOTE-522 study in triple-negative breast cancer. Transcript: Joyce A. O’Shaughnessy, MD: Let’s go on to the third data set, which is the KEYNOTE-522. We’re finally getting a big advance for patients with high-risk TNBC [triple-negative breast cancer] in …